Trials & Filings

Mixed Results for Lilly’s Ramucirumab

Cancer drug hits in gastric cancer trial, misses in breast cancer

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Eli Lilly and Co. has posted top-line results from RAINBOW and ROSE, two global Phase III studies of ramucirumab (IMC-1121B) in advanced gastric cancer and another in metastatic breast cancer. The drug, in combination with paclitaxel, met its primary endpoint in gastric cancer, improving overall survival, and also met its secondary endpoint of improved progression-free survival. However, a separate trial of ramucirumab in women with locally recurrent or metastatic breast cancer did not meet its ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters